High Potency Active Pharmaceutical Ingredients (HPAPI) Market, 2023 - Growing CMOS (Contract Manufacturing Organizations) Market
DUBLIN, November 15, 2017 /PRNewswire/ --
The "High Potency Active Pharmaceutical Ingredients (HPAPI) Global Market - Forecast to 2023" report has been added to Research and Markets' offering.
The global HPAPI market is poised to grow at a high single digit CAGR to reach $27,293.4 million by 2023
HPAPI market is mainly classified by customer base, by business type, by molecule type and Applications. The global HPAPI market is broadly classified as Innovative HPAPI and Generic HPAPI based on customer base. Based on business type, the market is classified into Captive HPAPI & Merchant HPAPI. HPAPI market is segmented on the basis of molecule type as Synthetic HPAPI and Biotech HPAPI. HPAPI market application segment is classified into Oncology, Cardiovascular, Central Nervous System, Hormonal, Glaucoma, Infectious, metabolic, Inflammation and other therapeutic applications.
Among Innovative & generic HPAPI, Innovative HPAPI occupies the major share during 2016 and generic HPAPIs expected to grow at a highest CAGR from 2016 to 2023. Among business type, Captive HPAPI occupies the major share during 2016 and Merchant HPAPI is expected to grow at a highest CAGR from 2016 to 2023. Among molecule type, Synthetic HPAPI occupied the major share during 2016 and is expected to grow at high single digit CAGR from 2016 to 2023 to reach $17,434.4 million by 2023. Among Application segment, Oncology commanded the larger revenue in 2016 and is expected to grow at highest CAGR from 2016 to 2023.
Increasing incidence of chronic and age-related diseases, rapid growth in oncology market, growing demand for Antibody Drug Conjugates (ADC), technological advancements in HPAPI market, growing CMOs are some of the factors which are driving the market. Requirement of large investments, stringent safety and handling specifications associated with production of HPAPI, stringent regulations are the factors hindering the market.
North America accounted for the highest market share in 2016 and followed by Europe. However, Asian countries especially China and India are the fastest growing regions with its growing demand for HPAPIs. Asia-Pacific is projected to grow with a highest CAGR from 2016 to 2023.
Factors Influencing Market
Drivers and Opportunities
- Increasing Incidence of Chronic and Age Related Diseases
- Rapid Growth in Oncology Market
- Growing Demand for Antibody Drug Conjugates (Adcs)
- Technological Advancements in HPAPI Market
- Growing Cmos (Contract Manufacturing Organizations) Market
Restraints and Threats
- Requirement of Large Investment
- Stringent Safety and Handling Specifications Associated With the Production of HPAPI
- Stringent Regulations
- Alternative Therapies to Cure the Cancer
Key Topics Covered:
1 Executive Summary
2 Introduction
3 Market Analysis
4 HPAPI Global Market, by Customer Base
5 HPAPI Global Market, by Business Type
6 HPAPI Global Market, by Molecule Type
7 HPAPI Global Market, by Applications
8 Regional Market Analysis
9 Competitive Landscape
10 Major Companies
Companies Mentioned
- Abbott Laboratories
- Abbvie Contract Manufacturing
- Adc Biotechnology
- Adc Therapeutics
- Aenova Group Gmbh
- Agno Pharma
- Ajinomoto (Althea Inc.)
- Alcami Corporation
- Alkermes Plc
- Almac Group
- Ampac Fine Chemicals
- Amri Global
- Anvi Pharma
- Astrazeneca(Spirogen)
- Asymchem Laboratories
- Avanthera S.A.
- Avara Pharmaceutical Services
- Axcellerate Pharma Services
- Bachem
- Baxter International
- Bayer
- Biocon Limited
- Biopharma Technology
- Biophore India Pharmaceuticals Pvt. Ltd
- Biotechnique
- Biovectra
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Bryllan Llc
- Buchiglas-Usa Corp.
- Cambrex Corporation
- Catalent Pharma Solutions Inc
- Celgene Biotechnology
- Cerbios Pharma Sa
- Chemcon
- Chemigran Pte Ltd.
- Cipla
- Consort Medical
- Custom Processing Services Inc
- Dalton Pharma Services
- Dec-Usa Inc.
- Dishman Group
- Dottikon Exclusive Synthesis
- Dr. Reddy's Laboratories
- Emcure Pharmaceuticals
- Esteve Quimica
- Eurofins Scientific
- Euticals
- Evonik Industries
- Evotec A.G.
- Fareva
- Farhispania Group
- Fermion
- Ferro Corporation
- Formosa Laboratories Inc.
- Fresenius Kabi
- Gp Pharm
- Granuels
- Helsin Advanced Synthesis.
- Heraeus
- Hikal Limited
- Hikma Pharmaceuticals
- Hovione
- Icrom S.P.A
- Idifarma Pharmaceutical Development S.L.
- Intas Biopharmaceuticals
- International Chemical Investors S. E
- Johnson Matthey
- Kyongbo Pharmaceutical Co. Ltd
- Laurus Synthesis Inc
- Lipocine
- Lonza Group
- Lupin Limited
- Mayne Pharma (Libertas Pharma Inc)
- Medichem
- Merck Kgaa
- Mersana Therapeutics Inc.
- Minakem High Potent
- Mitsubishi Tanabe Pharma Corp.
- Natco Pharma
- Neuland Health Sciences Private Limited
- Novartis
- Novasep Holding Sas
- Olon S.P.A.
- Opko Health
- Oso Biopharmaceuticals Manufacturing Llc
- Pcas
- Pfanstiehl
- Pfizer
- Pierre Fabre
- Piramal Pharma Solution
- Powder Systems Limited
- Procos S.P.A
- Project Pharmaceutics
- Qs Pharma Llc
- R-Pharm Germany Gmbh.
- Regis Technologies Inc.
- Scinopharm Taiwan Limited
- Seattle Genetics Inc.
- Seigried Holding
- Servier Cdmo
- Shilpa Medicare
- Stason Pharmaceuticals
- Strides Arcolabs
- Sundia Meditech
- Symbiosis Pharmaceutical Services
- Syntagon Ab
- Synthon Biopharmaceuticals
- Teva Pharmaceutical Industries
- Thermofisher Scientific (Patheon N.V.)
- Uman Pharma
- Umicore N.V.
- Vion Pharmaceuticals, Inc
- Vxp Pharma Services
- Wuxi Pharmatec
- Yprotech Limited
For more information about this report visit https://www.researchandmarkets.com/research/g9hdw2/high_potency
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article